CLN3 Protein (Battenin)

CLN3 Protein (Battenin)

Introduction

Cln3 Protein (Battenin) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

{{- <!-- CLN3 Protein Page - Ceroid Lipofuscinosis, Neuronal 3 Protein --> -}} [@johnson2023]

<div class="infobox infobox-protein"> [@cotman2010]

| Attribute | Value | [@storch2008]
|-----------|-------|
| Protein Name | Battenin |
| Gene | CLN3 |
| UniProt ID | Q9UQ16 |
| PDB Structure | No structure available |
| Molecular Weight | 48 kDa |
| Subcellular Localization | Lysosomal membrane, Endosomal membrane |
| Protein Family | CLN3 family, transmembrane proteins |

</div>}

Overview

CLN3 protein (also known as Battenin) is a lysosomal and endosomal transmembrane protein encoded by the CLN3 gene. It plays a critical role in maintaining lysosomal function, [autophagy](/entities/autophagy), and neuronal survival. Mutations in the CLN3 gene cause Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), also known as Batten disease^[1].

Structure

Primary Structure

CLN3 is a 438-amino acid integral membrane protein with the following features:

• Signal peptide: None (initiates at methionine)
• Transmembrane domains: 6 predicted transmembrane helices
• N-terminus: Cytosolic
• C-terminus: Cytosolic
• Large luminal loop: Contains potential N-linked glycosylation sites

Topology

CLN3 Protein (Battenin)

Introduction

Cln3 Protein (Battenin) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

{{- <!-- CLN3 Protein Page - Ceroid Lipofuscinosis, Neuronal 3 Protein --> -}} [@johnson2023]

<div class="infobox infobox-protein"> [@cotman2010]

| Attribute | Value | [@storch2008]
|-----------|-------|
| Protein Name | Battenin |
| Gene | CLN3 |
| UniProt ID | Q9UQ16 |
| PDB Structure | No structure available |
| Molecular Weight | 48 kDa |
| Subcellular Localization | Lysosomal membrane, Endosomal membrane |
| Protein Family | CLN3 family, transmembrane proteins |

</div>}

Overview

CLN3 protein (also known as Battenin) is a lysosomal and endosomal transmembrane protein encoded by the CLN3 gene. It plays a critical role in maintaining lysosomal function, [autophagy](/entities/autophagy), and neuronal survival. Mutations in the CLN3 gene cause Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), also known as Batten disease^[1].

Structure

Primary Structure

CLN3 is a 438-amino acid integral membrane protein with the following features:

• Signal peptide: None (initiates at methionine)
• Transmembrane domains: 6 predicted transmembrane helices
• N-terminus: Cytosolic
• C-terminus: Cytosolic
• Large luminal loop: Contains potential N-linked glycosylation sites

Topology

Cytosol
|
TM1 -- lumenal loop -- TM2
|
TM3 -- lumenal loop -- TM4
|
TM5 -- lumenal loop -- TM6
|
Cytosol

Post-Translational Modifications

• N-linked glycosylation: 4-5 potential sites in lumenal loops
• Phosphorylation: Serine and threonine residues (potential)
• Dimerization: May form homodimers

Function

Normal Function

CLN3/Battenin is a lysosomal membrane protein involved in:

Molecular Interactions

CLN3 interacts with:

• Rab proteins (RAB7, RAB9): Endosomal trafficking
• HSP70 family: Chaperone function
• Lysosomal ATPase subunits: Proton pump regulation
• Autophagy proteins: ULK1, ATG14

Disease Mechanism

In JNCL, CLN3 mutations lead to:

• Lysosomal dysfunction
• Accumulation of lipofuscins (ceroid)
• Impaired autophagy
• Progressive neuronal loss
• Synaptic dysfunction

Role in Disease

Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)

CLN3 mutations cause the most common form of Batten disease:

• Inheritance: Autosomal recessive
• Prevalence: 1 in 100,000 births
• Onset: 4-7 years of age
• Features: Vision loss, seizures, cognitive decline, motor dysfunction
• Progression: Rapidly progressive, fatal by late teens to early 20s

Common Disease-Causing Mutations

| Mutation | Type | Effect |
|----------|------|--------|
| Δex1-7 | Deletion | 73% of alleles, severe loss |
| P334L | Missense | Partial function |
| G225R | Missense | Partial function |
| Y181X | Nonsense | Truncated protein |

Therapeutic Targeting

Current Approaches

• Symptomatic treatment: Anticonvulsants, supportive care
• Physical/occupational therapy: Maintain function

Experimental Approaches

• Gene therapy: AAV-vector delivery to CNS^[2]
• Enzyme replacement: Being investigated
• Small molecules: Targeting lysosomal function
• Stem cell therapy: Investigational

Research Pipeline

| Approach | Stage | Notes |
|----------|-------|-------|
| AAV gene therapy | Preclinical | Delivers functional CLN3 |
| Small molecules | Discovery | Autophagy enhancers |
| Enzyme replacement | Early | Lysosomal delivery |

Interactions

CLN3 protein interacts with:

| Partner | Interaction Type | Function |
|---------|------------------|----------|
| RAB7 | Binding | Endosomal trafficking |
| RAB9 | Binding | Lysosomal transport |
| HSP70 | Chaperone | Protein folding |
| LAMP1/2 | Co-localization | Lysosomal membrane |

Background

The study of Cln3 Protein (Battenin) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• CLN3 Gene
• [Neuronal Ceroid Lipofuscinosis](/diseases/neuronal-ceroid-lipofuscinosis)
• [Batten Disease](/diseases/batten-disease)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)